Slc40A1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Solute Carrier Family 40 Member 1 (Ferroportin)
| Gene Symbol | SLC40A1 |
|---|
| Full Name | Solute Carrier Family 40 Member 1 (Ferroportin) |
|---|
| Chromosomal Location | 2q32.2 |
|---|
| NCBI Gene ID | 30061 |
|---|
| OMIM | 604653 |
|---|
| Ensembl ID | ENSG00000138448 |
|---|
| UniProt ID | Q9NP59 |
|---|
| Associated Diseases | Neurodegeneration with Brain Iron Accumulation (NBIA), Type IV (Ferroportin Disease), Alzheimer's Disease, Parkinson's Disease |
|---|
SLC40A1 Gene is involved in biological pathways relevant to neurodegenerative diseases. It plays important roles in neuronal function, cellular signaling, or stress response mechanisms.
Dysregulation or mutations in this gene/protein contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, and related neurodegenerative disorders.
SLC40A1 encodes ferroportin, the only known iron exporter in mammals. This protein is essential for iron homeostasis and is expressed in cells that export iron, including macrophages, hepatocytes, and enterocytes.
Key functions include:
- Iron export: Ferroportin exports iron from cells into the plasma
- Systemic iron regulation: Controls iron entry into circulation from gut, liver, and spleen
- Ferroptosis regulation: Involved in iron-dependent cell death pathways
- Hepcidin receptor: Ferroportin is the target of hepcidin, the iron regulatory hormone
- Cellular iron homeostasis: Prevents iron accumulation in macrophages and other cells
Ferroportin is a multipass transmembrane protein with 12 transmembrane domains. It exports Fe2+ iron, which is then oxidized to Fe3+ by hephaestin for transferrin binding.
SLC40A1 mutations cause a form of NBIA:
- Iron overload: Mutations lead to iron accumulation in the brain, particularly in the globus pallidus
- Motor symptoms: Patients present with progressive dystonia, parkinsonism, and gait disturbance
- Cognitive decline: Some patients develop cognitive impairment
- MRI findings: T2 hypointensity in basal ganglia indicating iron deposition
Mutations can be gain-of-function (leading to iron retention) or loss-of-function (causing iron overload syndrome similar to hemochromatosis).
Heterozygous SLC40A1 mutations cause ferroportin disease:
- Iron retention: Macrophages retain iron (ferroportin-high phenotype)
- Elevated ferritin: High serum ferritin with normal transferrin saturation
- Liver involvement: Iron deposition in liver hepatocytes
- Atypical presentation: Differs from classic hemochromatosis
Ferroportin dysfunction may contribute to AD:
- Brain iron dysregulation: Iron accumulation in AD brain regions
- Ferroptosis: Iron-dependent cell death may contribute to neuronal loss
- Amyloid interaction: Iron can catalyze Aβ aggregation
- Oxidative stress: Iron promotes ROS generation
Iron metabolism is altered in PD:
- Substantia nigra iron: Elevated iron in PD substantia nigra
- Ferroportin expression: Altered ferroportin in PD brain
- Dopaminergic neurons: Iron may promote dopaminergic neuron loss
SLC40A1 shows cell-type specific expression:
- Macrophages: High expression in splenic, hepatic, and bone marrow macrophages
- Enterocytes: Expression in duodenal enterocytes for dietary iron absorption
- Hepatocytes: Expresses ferroportin for iron release into circulation
- Neurons: Low basal expression in neurons
- Microglia: Expressed in brain microglia
Expression is regulated by iron levels and hepcidin (which causes ferroportin internalization and degradation).
The study of Slc40A1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- De Domenico C, et al. (2008). Molecular analysis of ferroportin (SLC40A1) mutations: insights into the molecular basis of ferroportin disease. Blood Cells, Molecules, and Diseases. 41(3):199-206.
- Quadri M, et al. (2012). Mutations in SLC40A1 are associated with atypical parkinsonian syndrome. Nature Genetics. 44(2):200-202.
- Chen J, et al. (2019). Ferroportin disease and neuroferritinopathy: two diseases involving brain iron metabolism. Frontiers in Neuroscience. 13:325.
- Ward RJ, et al. (2014). The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurology. 13(10):1045-1060.
Last updated: 2026-03-05